ACVRL1 and pulmonary arterial hypertension: Further studies show ACVRL1 mutants of PAH are related to the downregulation of SMAD1/5/9 signaling and confirm that the ACVRL1 mutants have negative effects on SMAD1/5 function (Piao et al., 2016).